Results 111 to 120 of about 1,458,916 (304)
Clinical Outcomes of Drug‐Eluting Stents and Drug‐Coated Balloons in Tortuous Small Coronary Lesions
ABSTRACT Background In small, tortuous coronary lesions, the long‐term comparative performance of drug‐coated balloon (DCB) angioplasty versus drug‐eluting stent (DES) treatment remains uncertain, despite both strategies being widely used in contemporary percutaneous coronary intervention (PCI) practice. Aims This study aimed to compare 3‐year clinical
Shunichiro Ishio +6 more
wiley +1 more source
Background Direct oral anticoagulants are the established drugs for treating pulmonary thromboembolism. The advantage of direct oral anticoagulants over conventional therapy for clot lysis and right ventricular unloading in the acute phase remains ...
Hiroya Hayashi +10 more
doaj +1 more source
ABSTRACT Background Transcatheter closure (TCC) of sinus venosus defects (SVD) using balloon‐expandable covered stents is an emerging alternative to surgery. ZephyrCS (Sahajanand Laser Technologies, Gandhinagar, India) is available in long lengths to suit SVD closure.
Pramod Sagar +3 more
wiley +1 more source
Direct Oral Anticoagulants: A Patient-centered Review
Since 2010, 4 new oral anticoagulants have been approved by the Food and Drug Administration with additional drugs in development. Major studies of atrial fibrillation and venous thromboembolism have shown the noninferiority, and the potential ...
Solomon, Jenna M., Hume,
core +1 more source
ABSTRACT Background Rotational atherectomy (RA) has undergone considerable technical modernization in recent years. This study evaluated whether RA performed in the contemporary era was associated with superior cardiovascular outcomes compared with the traditional era. Aims To compare the clinical characteristics and cardiovascular outcomes of patients
Ravi Vazirani +15 more
wiley +1 more source
Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review
Direct oral anticoagulants (not vitamin K antagonists), unlike standard oral anticoagulants (e.g. warfarin), have a predictable manifestation of the anticoagulant effect and the possibility of using a fixed dose without the need for constant monitoring ...
B. A. Tatarsky +2 more
doaj +2 more sources
Background and Objectives: Patients taking anticoagulants, particularly warfarin and non-vitamin K oral anticoagulants (NOACs), face an elevated risk of postoperative bleeding during minor oral surgeries, highlighting the urgent need to identify reliable
Iel-Yong Sung +4 more
core +1 more source
Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Chanan Shaul +5 more
wiley +1 more source
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz +5 more
wiley +1 more source
HOW THE HEMOSTASIS LABORATORY CAN HELP CLINICIANS TO MANAGE PATIENTS ON ORAL ANTICOAGULANTS
Oral anticoagulants are widely used to treat or prevent cardiovascular diseases in millions of patients worldwide. They are the drugs of choice for stroke prevention and systemic embolism in patients with non-valvular atrial fibrillation and prosthetic ...
Armando Tripodi
doaj +1 more source

